Bruker Announces EpicIFTM, Revolutionary Fluorescence Signal Removal Technology, Transforming CellScape Spatial Proteomics Platform

Rhea-AI Summary

Bruker (NASDAQ: BRKR) has announced EpicIF, a breakthrough technology for their CellScape Spatial Proteomics platform. This enhancement expands compatible fluorophore conjugated antibodies by nearly 10-fold and increases throughput up to 2-fold while maintaining tissue integrity. The technology combines a proprietary reagent with visible light to erase fluorescence signals from almost any fluorophore.

Alongside EpicIF, Bruker is releasing new CellScape Navigator software with an improved user interface. Both upgrades will be available for existing CellScape instruments, offering enhanced flexibility in multiplexed immunofluorescence experiments and compatibility with additional fluorescent readouts like RNA-ISH.

Positive

• 10-fold expansion in compatible fluorophore conjugated antibodies
• Up to 2-fold increase in throughput efficiency
• New software release with improved user interface
• Upgrade availability for existing CellScape instruments
• Enhanced compatibility with additional fluorescent readouts

Negative

• None.

Insights

Tech Analyst

The launch of EpicIF technology represents a significant advancement in spatial proteomics capabilities. The key improvements include a 10-fold increase in compatible antibody options and up to 2x throughput enhancement. This technological breakthrough addresses major bottlenecks in immunofluorescence research by expanding fluorophore compatibility while preserving tissue integrity.

The platform's commercial value stems from its ability to simplify complex workflows and reduce costs through improved antibody compatibility and assay optimization. The software upgrade with CellScape Navigator enhances user experience and operational efficiency. For Bruker, this positions them competitively in the growing spatial biology market, potentially driving instrument sales and upgrades for existing customers.

Market Research Analyst

This product enhancement strengthens Bruker's position in the spatial proteomics market, which is experiencing rapid growth due to increasing demand in cancer research and drug development. The improved capabilities address key customer pain points - workflow complexity and reagent compatibility. By enabling broader antibody compatibility and higher throughput, Bruker can potentially capture larger market share in the competitive spatial biology sector.

The timing of the announcement coinciding with SITC 2024 suggests strategic positioning to capture attention from key immunotherapy researchers. The ability to upgrade existing instruments indicates a smart strategy for both new sales and recurring revenue from the installed base.

New Technology Expands Antibody Compatibility and Doubles Throughput while maintaining Tissue Integrity and Lack of Cross-Reactivity

BILLERICA, Mass.--(BUSINESS WIRE)-- Bruker Corporation (Nasdaq: BRKR) today announced a major technological breakthrough in the CellScape™ Precise Spatial Proteomics platform for highly multiplexed immunofluorescence (IF). Launched in 2022, the CellScape platform has advanced the field of spatial proteomics with differentiated quantitative performance enabled by a unique combination of best-in-class resolution and high dynamic range (HDR) imaging. CellScape captures the entire continuum of protein expression in a biological sample—from least to most abundant—while capturing fine morphological details. CellScape utilizes directly-labeled primary antibodies, enabling a robust and modular chemistry that allows researchers to build assays by combining panels and/or individual markers, even after the conclusion of an experimental run. With this new technology, Bruker has further advanced the CellScape chemistry with EpicIF (Enhanced photobleaching in cyclic immunofluorescence), which expands the range of compatible commercially available fluorophore conjugated antibodies by nearly 10-fold, simplifies assay development, and increases throughput by up to 2-fold. EpicIF enhances photobleaching efficacy combining a proprietary reagent with visible light to gently erase fluorescence signal from nearly any fluorophore and, like the prior version, the epitopes are preserved while maintaining tissue integrity.

Human FFPE tonsil, 48-plex proteomics assay captured on the CellScape Spatial Proteomics Instrument (inset) using EpicIF technology (Photo: Business Wire)

EpicIF is supported by the concurrent release of a new version of the software. The new software, CellScape™ Navigator, also introduces a more intuitive user interface and easy experiment setup. Both EpicIF and CellScape Navigator will be available as upgrades to current CellScape instruments. “This breakthrough gives scientists an unmatched level of flexibility in their highly multiplexed IF experiments,” said Ranga Partha, PhD, Senior Vice President of Product Management and Marketing at Bruker Spatial Biology. “This new advancement builds on the best-in-class performance of the CellScape, which already offers differentiated quantitative performance, reliability, and modularity at any time. Now, by enabling the erasure of previously photostable fluorophore signals, researchers can choose a wider selection of antibody conjugates than ever before. In addition, EpicIF enables compatibility of the CellScape platform with additional fluorescent readouts, such as RNA-ISH. It’s a leap forward in versatility for high-throughput spatial proteomics and we’re thrilled to offer this transformative technology to our customers.”

Oliver Braubach, PhD, Director of R&D Assays at Bruker Spatial Biology, added, “We have developed a solution that overcomes the limitations of traditional multiplexing. The ability to erase signal from a wide range of organic fluorescent dyes without damaging tissues not only simplifies workflows, but also allows scientists to use antibodies validated in other workflows, providing cost and time savings on assay optimization. The use of directly-labeled primary antibodies also eliminates the cross-reactivity observed in other spatial proteomic techniques that rely on secondary antibodies." Bruker Spatial Biology will be sharing more about this new advancement at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting from Nov 8-10 in Houston, Texas at booth #419. For additional information, visit www.brukerspatialbiology.com/EpicIF.

About Bruker Spatial Biology

Bruker Spatial Biology, a division of Bruker Corporation, provides advanced spatial solutions, including instruments, assays, software, and services to support life sciences research from discovery to translation. Best-in-class technologies include the CosMx® SMI with data analysis by the AtoMx™ SIP, GeoMx® DSP, CellScape™ platform, and nCounter® system. Canopy Multiomic Services provides access to these technologies for biopharmaceutical research, custom assay development, and clinical sample testing. Learn more at www.brukerspatialbiology.com.

About Bruker Corporation – Leader of the Post-Genomic Era (Nasdaq: BRKR)

Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker’s high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in applied and biopharma applications, in microscopy and nanoanalysis, as well as in industrial and cleantech research, and next-gen semiconductor metrology in support of AI. Bruker offers differentiated, high value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit www.bruker.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241108899571/en/

Investor Contact:

Joe Kostka

Director, Investor Relations

Bruker Corporation

T: +1 (978) 313-5800

E: Investor.Relations@bruker.com

Media Contact:

Kevin Gamber

Vice President, Downstream Marketing

Bruker Spatial Biology

E: kevin.gamber@bruker.com

Source: Bruker Corporation

FAQ

What is Bruker's new EpicIF technology for the CellScape platform?

EpicIF is a fluorescence signal removal technology that expands antibody compatibility by 10-fold and doubles throughput while maintaining tissue integrity. It uses a proprietary reagent with visible light to erase fluorescence signals.

How does EpicIF improve Bruker's (BRKR) CellScape platform performance?

EpicIF improves CellScape by expanding compatible antibodies 10-fold, increasing throughput up to 2-fold, simplifying assay development, and enabling compatibility with additional fluorescent readouts like RNA-ISH.

What software updates accompany Bruker's (BRKR) EpicIF technology release?

Bruker is releasing CellScape Navigator, a new software version featuring a more intuitive user interface and easier experiment setup, available as an upgrade for current CellScape instruments.